Medtronic wins FDA nod for world’s smallest defibrillation lead
April 26, 2025
Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle placement.
Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle placement.
Clarius is the first to offer an FDA-cleared AI-powered prostate measurement tool on a handheld ultrasound scanner—empowering primary care and urology physicians to assess patients on the spot without waiting for specialist referrals
Researchers from the PRODI Center for Protein Diagnostics at Ruhr University Bochum, Germany, and the biotech company betaSENSE have now discovered a biomarker in the spinal fluid that facilitates a reliable diagnosis at an early stage and can shed light on the progression of the disease and the effect of a therapy. They report their findings in the journal EMBO Molecular Medicine from April 25, 2025.
New studies offer insight into disease’s treatment, lingering symptoms
LEM Surgical announced that it received FDA 510(k) clearance for its Dynamis robotic surgical system for hard tissue surgery.
ENGLEWOOD, Colo., April 24, 2025 /PRNewswire/ — CIRCA Scientific is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the PeriCross™ Epicardial Access Kit (formerly Rook®), a purpose-built solution designed to enable controlled and efficient access to the pericardial space via a subxiphoid approach.
Indiana University School of Medicine scientists have developed a powerful new imaging technique to study bone marrow in mouse models. By overcoming key challenges unique to imaging this complex tissue, this advancement could support future drug development and therapies for conditions involving bone marrow, including cancers, autoimmune diseases and musculoskeletal disorders.
Researchers at the University of California San Diego School of Medicine have identified a potential new treatment, an investigational drug called lorundrostat, for individuals with uncontrolled or treatment-resistant hypertension, commonly known as high blood pressure.
Researchers have identified a key enzyme driving forms of Parkinson’s disease, and have shown how blocking it restores normal function in animal and cell models, offering a promising new drug target for the condition.
Innovative mesh aims to improve patient outcomes by naturally absorbing into the body post-surgery.